{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:13Z","timestamp":1794009073359,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001808","name":"Public Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016145","name":"Ministerio de Sanidad, Consumo y Bienestar Social","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.11.075","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T09:34:12Z","timestamp":1641288852000},"page":"666-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-1387","authenticated-orcid":false,"given":"R.","family":"Villena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7298-4884","authenticated-orcid":false,"given":"M.","family":"Bast\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Santolaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.vaccine.2021.11.075_b0005","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"issue":"9508","key":"10.1016\/j.vaccine.2021.11.075_b0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","article-title":"Clinical recognition of meningococcal disease in children and adolescents","volume":"367","author":"Thompson","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.11.075_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2018.00321","article-title":"Invasive meningococcal disease in the vaccine era","volume":"6","author":"Nadel","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.vaccine.2021.11.075_b0020","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.11.075_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: Biology, microbiology, and epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.11.075_b0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2021.11.075_b0035","unstructured":"Ministerio de Salud de Chile, Subsecretar\u00eda de Salud P\u00fablica, Departamento de Epidemiolog\u00eda. Circular B51 No8 2017: Vigilancia epidemiol\u00f3gica de casos sospechosos de Enfermedad Meningoc\u00f3cica (A.39) y medidas de control 2017. Available at: http:\/\/epi.minsal.cl\/enfermedad-meningococcica\/ [accessed 29 August 2020]."},{"key":"10.1016\/j.vaccine.2021.11.075_b0040","unstructured":"Ministerio de Salud de Chile, Subsecretar\u00eda de Salud P\u00fablica, Decreto 7 Aprueba el reglamento sobre notificaci\u00f3n de enfermedades transmisibles de declaraci\u00f3n obligatoria y su vigilancia N\u00fam. 7.- Santiago, 12 de marzo de 2019 Available at https:\/\/diprece.minsal.cl\/wp-content\/uploads\/2020\/08\/Decreto-7.pdf. [accessed 23 June 2021]."},{"key":"10.1016\/j.vaccine.2021.11.075_b0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4067\/S0370-41062012000600002","article-title":"Historia y epidemiolog\u00eda del meningococo","volume":"83","author":"Wilhelm","year":"2012","journal-title":"Rev Chil Pediatr"},{"key":"10.1016\/j.vaccine.2021.11.075_b0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4067\/S0716-10182014000400001","article-title":"Laboratory surveillance for invasive meningococcal disease in Chile, 2006\u20132012","volume":"31","author":"Araya","year":"2014","journal-title":"Rev Chil Infectolog\u00eda"},{"issue":"46","key":"10.1016\/j.vaccine.2021.11.075_b0055","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1016\/j.vaccine.2019.09.050","article-title":"Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile","volume":"37","author":"Villena","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.11.075_b0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3201\/eid2102.140746","article-title":"Neisseria meningitidis ST-11 clonal complex, Chile, 2012","volume":"21","author":"Araya","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.11.075_b0065","first-page":"350","article-title":"Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012","volume":"30","author":"Moreno","year":"2013","journal-title":"Rev Chil Infectol"},{"key":"10.1016\/j.vaccine.2021.11.075_b0070","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4067\/S0034-98872013000800001","article-title":"Emergence of W135 meningococcal serogroup in Chile during 2012","volume":"141","author":"Valenzuela","year":"2013","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.vaccine.2021.11.075_b0075","doi-asserted-by":"crossref","unstructured":"Valenzuela MT, Ma\u00f1alich J, Diaz J, Linazasoro I, Castillo L, Morales AM, Villena R. Plan de acci\u00f3n nacional frente a la emergencia de la cepa W-135 responsable de Enfermedad Meningoc\u00f3cica Invasora en Chile, 2012-2013. Rev Med Chil 2019;147: 776\u201386. https:\/\/doi.org\/10.4067\/S0034-98872019000600776.","DOI":"10.4067\/S0034-98872019000600776"},{"key":"10.1016\/j.vaccine.2021.11.075_b0080","unstructured":"Instituto Nacional de Estad\u00edsticas, Chile https:\/\/www.ine.cl\/ [accessed 23 January 2021]."},{"issue":"9","key":"10.1016\/j.vaccine.2021.11.075_b0085","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): A case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"issue":"37","key":"10.1016\/j.vaccine.2021.11.075_b0090","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","article-title":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.11.075_b0095","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/21645515.2015.1010885","article-title":"Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country","volume":"11","author":"Izquierdo","year":"2015","journal-title":"Hum Vaccines Immunother"},{"issue":"30 Suppl 2","key":"10.1016\/j.vaccine.2021.11.075_b0100","doi-asserted-by":"crossref","first-page":"B37","DOI":"10.1016\/j.vaccine.2011.12.074","article-title":"Meningococcal disease from the public health policy perspective","volume":"30","author":"Black","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.11.075_b0105","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/21645515.2018.1458175","article-title":"Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines","volume":"14","author":"Villena","year":"2018","journal-title":"Hum Vaccines Immunother"},{"issue":"40","key":"10.1016\/j.vaccine.2021.11.075_b0110","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.11.075_b0115","first-page":"1","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA \u2013 TT) on serogroup A meningococcal meningitis and carriage in Chad : a community trial","volume":"6736","author":"Djingarey","year":"2013","journal-title":"Lancet"},{"issue":"27 Suppl 2","key":"10.1016\/j.vaccine.2021.11.075_b0120","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: The experience in England and Wales","volume":"24","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.11.075_b0125","doi-asserted-by":"crossref","unstructured":"Knol Mirjam J, Ruijs Wilhelmina LM, Antonise-Kamp Laura, de Melker Hester E, van der Ende Arie. Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Euro Surveill. 2018;23(16):pii=18-00158. 10.2807\/1560-7917. ES.2018.23.16.18-00158.","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158"},{"key":"10.1016\/j.vaccine.2021.11.075_b0130","unstructured":"World Health Organization. Meningococcal vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(47):521\u201340. Available at http:\/\/www.who.int\/entity\/wer\/2011\/wer8647.pdf?uaD1 [accessed 23 January 2021]."},{"key":"10.1016\/j.vaccine.2021.11.075_b0135","unstructured":"Centers for Disease Control and Prevention Guidance for the Evaluation and Public Health Management of Suspected Outbreaks of Meningococcal Disease Version 2.0 September 28, 2019 Available at : https:\/\/www.cdc.gov\/meningococcal\/downloads\/meningococcal-outbreak-guidance.pdf [accessed 16 April 2021]."},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.075_b0140","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/INF.0000000000000228","article-title":"A Consensus Statement: meningococcal disease among infants, children and adolescents in Latin America","volume":"33","author":"R\u00fcttimann","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.11.075_b0145","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease Annual Epidemiological Report for 2017. Stockholm: 2019. Available at https:\/\/ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2017 [accessed 16 April 2021]."},{"key":"10.1016\/j.vaccine.2021.11.075_b0150","unstructured":"Autralian government, Department of Health Invasive meningococcal disease national surveillance Available at https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/5FEABC4B495BDEC1CA25807D001327FA\/$File\/IMD-surveil-report-Jan-June-2019.pdf report [accessed 23 January 2021]."},{"key":"10.1016\/j.vaccine.2021.11.075_b0155","unstructured":"Centers for Disease Control and Prevention Meningococcal Disease Available at https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html [accessed 23 January 2021]."},{"issue":"21","key":"10.1016\/j.vaccine.2021.11.075_b0160","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.2020.20449","article-title":"Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal","volume":"324","author":"Rodrigues","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.11.075_b0165","doi-asserted-by":"crossref","unstructured":"Ladhani S, Andrews N, Parikh S, Campbell H, White J, Edelstein M, et al. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England N Engl J Med 2020;382(4):309-317. 10.1056\/NEJMoa1901229.","DOI":"10.1056\/NEJMoa1901229"},{"key":"10.1016\/j.vaccine.2021.11.075_b0170","doi-asserted-by":"crossref","unstructured":"Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009;8(7):851-61. 10.1586\/erv.09.48.","DOI":"10.1586\/erv.09.48"},{"issue":"16","key":"10.1016\/j.vaccine.2021.11.075_b0175","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.vaccine.2017.03.010","article-title":"Meningococcal Study Group. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil","volume":"35","author":"Andrade","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.11.075_b0180","doi-asserted-by":"crossref","unstructured":"Evellyn do Macedo L, Ferreira VM, Feitosa CA, Nunes AMPB, Campos LC, S\u00e1fadi MAP. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil. Hum Vaccines Immunother 2018;14:1131\u20137. 10.1080\/21645515.2017.1415682.","DOI":"10.1080\/21645515.2017.1415682"},{"key":"10.1016\/j.vaccine.2021.11.075_b0185","doi-asserted-by":"crossref","unstructured":"Tully J, Viner R, Coen P, Stuart J, Zambon M, Peckham C, et al Risk and protective factors for meningococcal disease in adolescents: matched cohort study BMJ 2006 25;332(7539):445\u201350. 10.1136\/bmj.38725.728472.BE.","DOI":"10.1136\/bmj.38725.728472.BE"},{"key":"10.1016\/j.vaccine.2021.11.075_b0190","doi-asserted-by":"crossref","unstructured":"Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk Factors for Meningococcal Disease in College Students. JAMA (2001);286: 688-93 10.1001\/jama.286.6.688","DOI":"10.1001\/jama.286.6.688"},{"key":"10.1016\/j.vaccine.2021.11.075_b0195","unstructured":"WHO vaccine-preventable diseases: monitoring system. 2020 global summary Available at https:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules?sc%5Bd%5D=&sc%5Bv%5D%5B%5D=MENC_CONJ&sc%5BOK%5D=OK [accessed 23 January 2021]"},{"key":"10.1016\/j.vaccine.2021.11.075_b0200","doi-asserted-by":"crossref","unstructured":"Borgono JM, Rodriguez_H, Garc\u00eda J, Canepa I. Efficacy of rifampicin in thetreatment of meningococcus carriers. Rev Chil Pediatr 1981;52:146\u20138.","DOI":"10.4067\/S0370-41061981000200007"},{"issue":"43","key":"10.1016\/j.vaccine.2021.11.075_b0205","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1016\/j.vaccine.2014.08.015","article-title":"Meningococcal carriage prevalence in university students, 1824 years of age in Santiago Chile","volume":"32","author":"Rodriguez","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.11.075_b0210","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jiph.2015.12.011","article-title":"Prevalence of meningococcal carriage in children and adolescents aged 10\u201319 years in Chile in 2013","volume":"9","author":"D\u00edaz","year":"2016","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.vaccine.2021.11.075_b0215","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.075_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247991","article-title":"Oropharyngeal meningococcal carriage in children and adolescents, a single center study in Buenos Aires Argentina","volume":"16","author":"Gentile","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2021.11.075_b0225","doi-asserted-by":"crossref","unstructured":"The MenAfriCar consortium The diversity of meningococcal carriage across the African Meningitis Belt and the impact of vaccination with a group A meningococcal conjugate vaccine J Infect Dis2015;212(8):1298\u2013307. 10.1093\/infdis\/jiv211.","DOI":"10.1093\/infdis\/jiv211"},{"issue":"4","key":"10.1016\/j.vaccine.2021.11.075_b0230","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/infdis\/jix596","article-title":"Limited impact of adolescent meningococcal ACWY vaccination on Neisseria meningitidis serogroup W carriage in university students","volume":"217","author":"Oldfield","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.11.075_b0235","doi-asserted-by":"crossref","unstructured":"Read RC, Baxter D, Chadwick DR, Faust S, Finn A, Gordon S, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123\u201331 10.1016\/S0140-6736(14)60842-4.","DOI":"10.1016\/S0140-6736(14)60842-4"},{"issue":"9911","key":"10.1016\/j.vaccine.2021.11.075_b0240","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA \u2013 TT) on serogroup A meningococcal meningitis and carriage in Chad : a community trial","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.11.075_b0245","doi-asserted-by":"crossref","unstructured":"Grundy E, Albala C, Allen E, Dangour A, Elbourne D, Uauy R. Grandparenting and psychosocial health among older Chileans: A longitudinal analysis. Aging & Mental Health 16:8, 1047\u201357. doi: 10.1080\/13607863.2012.692766.","DOI":"10.1080\/13607863.2012.692766"},{"key":"10.1016\/j.vaccine.2021.11.075_b0250","unstructured":"Grandparenting in Europe: family policy and grandparents\u2019 role in providing childcare. Avalibale at https:\/\/kinship.org.uk\/wp-content\/uploads\/2020\/02\/Grandparenting-in-Europe-0313.pdf [accessed 23 September 2021]."},{"key":"10.1016\/j.vaccine.2021.11.075_b0255","unstructured":"2018 Grandparents today national survey. Multicultural Report: Hispanic\/Latinx Grandparents Available at https:\/\/www.aarp.org\/content\/dam\/aarp\/research\/surveys_statistics\/life-leisure\/2019\/aarp-grandparenting-study-hispanic-latinx.doi.10.26419-2Fres.00289.005.pdf [accessed 23 September 2021]."},{"key":"10.1016\/j.vaccine.2021.11.075_b0260","unstructured":"Informe Regional SIREVA 2017, Argentina Informaci\u00f3n sobre la vigilancia de las neumon\u00edas y meningitis bacterianas. SIREVA II. OPS. 2019 Neisseria meningitidis http:\/\/antimicrobianos.com.ar\/ATB\/wp-content\/uploads\/2021\/01\/Meningo-2019.pdf [accessed 23 June 2021]."},{"key":"10.1016\/j.vaccine.2021.11.075_b0265","doi-asserted-by":"crossref","unstructured":"Ladhani S, Campbell H, Andrews N, Parikh S, White J, Edelstein M, et al First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England Clin Infect Dis .2020 Aug 26;ciaa1244. 10.1093\/cid\/ciaa1244.","DOI":"10.1093\/cid\/ciaa1244"},{"issue":"1","key":"10.1016\/j.vaccine.2021.11.075_b0270","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12879-020-05104-5","article-title":"A phase 2b\/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years","volume":"20","author":"Borja-Tabora","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.11.075_b0275","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines8040624","article-title":"Different long-term duration of seroprotection against Neisseria meningitidis in adolescents and middle-aged adults after a single meningococcal ACWY conjugate vaccination in The Netherlands","volume":"8","author":"Mi","year":"2020","journal-title":"Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21015498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21015498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:07:41Z","timestamp":1759403261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21015498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X21015498"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}